Endocrine therapy for the treatment of postmenopausal women with breast cancer

References

• Brock R. The Life and Works of Astley Cooper. E&S Livingston Ltd, London, UK (1952).
   Google Scholar
• Beatson G. On the treatment of inoperable cases of the mammary: suggestions for a new method of treatment with illustrative cases. Lancet2, 104–165 (1986).
   Google Scholar
• Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg.115(6), 1192–1200 (1942).
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer. J. Clin.22(4), 232–240 (1972).
   PubMedGoogle Scholar
• Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res.12(2), 134–141 (1952).
   PubMed Web of Science ®Google Scholar
• Dodds E, Lawson W, Noble RL. Biological effects of the synthetic oestrogen substance 4:4-dihydroxy a β-diethylstilbene. Lancet1, 1389–1391 (1938).
   Google Scholar
• Jensen EV, Block GE, Smith S et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst. Monogr.34, 55–70 (1971).
   PubMedGoogle Scholar
• Toft D, Shyamala G, Gorski J. A receptor molecule for estrogens: studies using a cell-free system. Proc. Natl Acad. Sci. USA57(6), 1740–1743 (1967).
   PubMed Web of Science ®Google Scholar
• Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer.25(2), 270–275 (1971).
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burnstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol.20(15), 3317–3327 (2002).
   PubMed Web of Science ®Google Scholar
• Judd HL, Judd GE, Lucas WE et al. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab.39(6), 1020–1024 (1974).
   PubMed Web of Science ®Google Scholar
• Richards JS, Hickey GK, Chen SA et al. Hormonal regulation of estradiol biosynthesis, aromatase activity, and aromatase mRNA in rat ovarian follicles and corpora lutea. Steroids50(4–6), 393–409 (1987).
   PubMedGoogle Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med.348(24), 2431–2442 (2003).
   PubMed Web of Science ®Google Scholar
• Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev. Anticancer Ther.2(2), 151–160 (2002).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet351(9114), 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365(9453), 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Belfiglio M, Valentini M, Pellegrini F et al. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer104(11), 2334–2339 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J. Natl Cancer Inst.93(6), 456–462 (2001).
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. Natl Cancer Inst.88(21), 1543–1549 (1996).
   PubMed Web of Science ®Google Scholar
• Delozier T, Speilmann M, Mace-Lesec’h J et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J. Clin. Oncol.18(20), 3507–3512 (2000).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst.93(9), 684–690 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Forest AP, Everington D et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br. J. Cancer74(2), 297–299 (1996).
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst.95(23), 1758–1764 (2003).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol.23(36), 9312–9318 (2005).
   PubMed Web of Science ®Google Scholar
• Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat.91(3), 249–258 (2005).
   PubMed Web of Science ®Google Scholar
• Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res.7(3), R284–R290 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan VC. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat. Rep.60(10), 1409–1419 (1976).
   PubMedGoogle Scholar
• Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Cuzick J Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet360(9336), 817–824 (2002).
   PubMed Web of Science ®Google Scholar
• Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet352(9122), 98–101 (1998).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maissonneuve P, Rotmensz N et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J. Natl Cancer Inst.95(2), 160–165 (2003).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet361(9354), 296–300 (2003).
   PubMed Web of Science ®Google Scholar
• Shen Y, Costantino JP, Qin J. Tamoxifen Chemoprevention treatment and time to first diagnosis of estrogen receptor – negative breast cancer. J. Natl Cancer Inst.100, 1448–1453 (2008).
   PubMedGoogle Scholar
• Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med.326(13), 852–856 (1992).
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol.12(5), 992–997 (1994).
   PubMed Web of Science ®Google Scholar
• Bruning PF, Bonfrer JM, Hart AA et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer58(4), 497–499 (1988).
   PubMed Web of Science ®Google Scholar
• Love RR, Wiebe DA, Feyzi JM et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl Cancer Inst.86(20), 1534–1539 (1994).
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Enholm C et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol.14(2), 429–433 (1996).
   PubMed Web of Science ®Google Scholar
• Anker G, Lonning PE, Ueland PM et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int. J. Cancer.60(3), 365–368 (1995).
   PubMed Web of Science ®Google Scholar
• Carstensen J, Rosell J, Bengtsson N-O et al. Prolonged tamoxifen therapy: effects on contralateral breast cancer, endometrial cancer and cardiovascular mortality. Breast Cancer Res. Treat.82(Suppl. 1), (2003) (Abstract 425).
   Google Scholar
• Vogel CL, Shermano I, Schoenfelder J et al. Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol.11(2), 345–350 (1993).
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Ellmen J, Vuorinen J et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat.56(2), 133–143 (1999).
   PubMed Web of Science ®Google Scholar
• Holli K, Valavaara R, Blanco G et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J. Clin. Oncol.18(20), 3487–3494 (2000).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Marcus C, Holmes F et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology45(5), 344–345 (1988).
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab.87(8), 3609–3617 (2002).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat.65(2), 125–134 (2001).
   PubMed Web of Science ®Google Scholar
• Fisher B, Constantino JP, Wickerham DL et al., Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst.97(22), 1652–1662 (2005).
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Wang J, Constantino JP et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J. Natl Cancer Inst.95(4), 302–307 (2003).
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer98(9), 1802–1810 (2003).
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol.25(5), 486–492 (2007).
   PubMed Web of Science ®Google Scholar
• Vogel VG, Constatntino JP, Dickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295(23), 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Santen RJ, Worgul TJ, Lipton A et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann. Intern. Med.96(1), 94–101 (1982).
   PubMed Web of Science ®Google Scholar
• Plowman PN, Nicholson RI, Walker KJ. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br. J. Cancer54(6), 903–909 (1986).
   PubMed Web of Science ®Google Scholar
• Blamey RW, Jonat W, Kaufmann M et al. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer28A(4–5), 810–814 (1992).
   PubMed Web of Science ®Google Scholar
• Dixon AR, Robertson JF, Jackson L et al. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br. J. Cancer62(5), 868–870 (1990).
   PubMed Web of Science ®Google Scholar
• Harvey HA, Lipton A, Max DT et al. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J. Clin. Oncol.3(8), 1068–1072 (1985).
   PubMed Web of Science ®Google Scholar
• Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol.26(10), 1671–1676 (2008).
   PubMed Web of Science ®Google Scholar
• Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr. Relat. Cancer6(1), 75–92 (1999).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Miki Y, Ohuchi N et al. Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer15(4), 270–277 (2008).
   PubMed Web of Science ®Google Scholar
• Buzdar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol.19(14) 3357–3366 (2001).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer83(6), 1142–1152 (1998).
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol.18(7), 1399–1411 (2000).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21(11), 2101–2109 (2003).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol.19(10), 2596–2606 (2001).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer92(9), 2247–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, Phase III study. Am. J. Clin. Oncol.26(3), 317–322 (2003).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer39(12), 1684–1689 (2003).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol.18(22), 3758–3767 (2000).
   PubMed Web of Science ®Google Scholar
• Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized Phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol.14(9), 1391–1398 (2003).
   PubMed Web of Science ®Google Scholar
• Bertelli G, Garrone O, Merlano M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology69(6), 471–477 (2005).
   PubMed Web of Science ®Google Scholar
• Iaffaioli RV, Formato R, Tortoriello A et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br. J. Cancer92(9), 1621–1625 (2005).
   PubMed Web of Science ®Google Scholar
• Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J. Clin. Oncol.18(11), 2234–2244 (2000).
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet359(9324), 2131–2139 (2002).
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9(1), 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353(26), 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Mauriac L et al. BIG I-98: a randomized double-blind Phase III study of letrozole and tamoxifen given in sequence as adjuvant therapy for postmenopausal women with receptor-positive cancer. Cancer Res.69(Suppl. 2), S66 (2009).
   Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet366(9484), 455–462 (2005).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Gnant M, Griel R et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res.69(Suppl. 2), 67S (2009).
   Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350(11), 1081–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet369(9561), 559–570 (2004).
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst. Rev.1, CD000486 (2001).
   Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol.14(10), 2738–2746 (1996).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst.97(17), 1262–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J. Clin. Oncol.25(15), 2006–2011 (2007).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med.349(19), 1793–1802 (2003).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Tu D, Pater JL et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res. Treat.99(3), 295–300 (2006).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). ASCO Annual Meeting Proceedings. J. Clin. Oncol.23(16 Suppl.), S527 (2005).
   Google Scholar
• Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr. Relat. Cancer7(1), 17–28 (2000).
   PubMed Web of Science ®Google Scholar
• Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol.20(16), 3386–3395 (2002).
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol.22(9), 1605–1613 (2004).
   PubMed Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J. Clin. Oncol.26(10), 1664–1670 (2008).
   PubMed Web of Science ®Google Scholar
• Perey L, Parideans R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of Phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol.18(1), 64–69 (2007).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. Expression of the 21 gene recurrence score assay and prediction of clinical benefit from tamoxifen in NSABP study B14 and chemotherapy in NSABP study B-20. Breast Cancer Res. Treat.88(Suppl. 15), S24 (2004).
   Google Scholar
• Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol.24(23), 3726–3734 (2006).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med.355(6), 560–569 (2006).
   PubMed Web of Science ®Google Scholar
• Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat.24(2), 85–95 (1992).
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res.11(13), 4741–4748 (2005).
   PubMed Web of Science ®Google Scholar
• Mackey JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium. TX, USA, 14–17 December 2006 (Abstract 3).
   Google Scholar
• Schafer JM, Bentrem DJ, Takei H et al. A mechanism of drug resistance to tamoxifen in breast cancer. J. Steroid Biochem. Mol. Biol.83(1–5), 75–83 (2002).
   PubMed Web of Science ®Google Scholar
• Kaklamani VG, Cicconi J, Gradishar W et al. Increased HER2 expression in women with recurrent ER positive breast cancer. ASCO Annual Meeting Proceedings. J. Clin. Oncol.25(18S), 10516 (2007).
   Google Scholar
• Cristofanilli M, Valero V, Mangalik A et al. A Phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings. J. Clin. Oncol.26(18 Suppl.), S1012 (2008).
   PubMedGoogle Scholar
• Dickler M. A pilot Phase II trial of bevacizumab and letrozole for hormone refractory metastatic breast cancer. Presented at: American Society of Clinical Oncology Breast Cancer Symposium. Washington, DC, USA, 5–7 September 2008.
   Google Scholar
• Winer EP, Hudis C, Burnstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol.23(3), 619–629 (2005).
   PubMed Web of Science ®Google Scholar